Advertisement

Eicosanoids pp 137-154 | Cite as

Prostanoid Receptors

Classification, Characterisation and Therapeutic Relevance
  • Robert A. Coleman
Chapter
Part of the NATO ASI Series book series (NSSA, volume 283)

Abstract

Functional. The functional approach to receptor classification was pioneered by Ahlquist (1948), who demonstrated that adrenoceptors could be subclassified into α-and β-subtypes on the basis of the rank order of potency of a series of cathecholamines. Although the power of this approach was not immediately acknowledged, it gradually became accepted, and has now been utilised in the classification of most if not all known hormone receptors. It has been of crucial importance in the classification of prostanoid receptors, leading to the now generally accepted conclusion that there are receptors specific for each of the naturally occurring prostanoids, and that there are subtypes of at least one of these (Coleman et al., 1994b). The first tentitive steps towards the classification of prostanoid receptors were made by Pickles in 1967, who reported that a range of different prostanoid analogues exhibited different rank orders of agonist potency in a range of different tissues. This report was followed by those of Andersen and Ramwell (1974), Andersen et al. (1980) and Gardiner and Collier (1980), who provided further evidence for distinct rank orders of prostanoid agonist potency in different systems both in vitro and in vivo. However, it was the work of Kennedy et al. (1982) that provided the basis for the classification of prostanoid receptors that is now universally accepted (see Coleman et al., 1994b, Table 1). This classification states that there are five basic classes of receptor, DP, EP, FP, IP and TP, with subdivision of the EP class into four subtypes, EP1, EP2, EP3 and EP4. As yet, there is no conclusive evidence of subtypes of any of the other four classes, but it seems unlikely that such subdivision is restricted to EP-receptors, and it has been suggested that there are subtypes of both DP and TP-receptors. Further subdivision of EP-receptors is now apparent following the discovery that there are a number of isoforms of the EP3-receptor class (Namba et al., 1993).

Keywords

Radioligand Binding Agonist Potency Prostanoid Receptor Human Myometrium Recombinant Receptor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abramowitz, M., Boie, Y., Nguren, T., Rushmore, T.H., Baynes, M.A., Metters, K.M., Slipetz, D.M. and Grygorczyk, R., 1994, Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol Chem., 269: 2632–2636.Google Scholar
  2. Ahlquist, R.R, 1948, A study of the adrenotropic receptors. Am. J. Physiol., 153: 586–600.PubMedGoogle Scholar
  3. Alvarez, R., Eglen, R.M., Chang, L.F., Bruno, J.J., Artis, D.R., Kluge, A.F. and Whiting, R.L., 1991, Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin. Prostaglandins, 42:105–119.PubMedGoogle Scholar
  4. An, S., Yang, J., Xia, M. and Goetzl, E.J., 1993, Cloning and expression of the EP2 subtype of human receptors for prostaglandin E2. Biochem. Biophys. Res. Commun., 197: 263–270.PubMedCrossRefGoogle Scholar
  5. Andersen, N.H., Eggerman, T.L. Harker, L.A, Wilson, C.H. and De, B., 1980, On the multiplicity of platelet prostaglandin receptors. 1. Evaluation of competitive antagonism by aggregometry. Prostaglandins, 19:711–734.PubMedGoogle Scholar
  6. Andersen, N.H. and Ramwell, P.W., 1974, Biological aspects of prostaglandins. Arch. Intern. Med., 133: 30–50.PubMedCrossRefGoogle Scholar
  7. Birrell, G.J. McQueen, D.S., Iggo, A., Coleman, R.A. and Grubb B.D., 1991, PGI2-induced sensitization of articular mechanonociceptors. Neurosci Lett., 124: 5–8.PubMedCrossRefGoogle Scholar
  8. Boie, Y., Rushmore, T.H., Darmon-Goodwin, A., Grygorczyk, R. Slipetz, D.M. Metters, K.M. and Abramovitz, M., 1994, Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem, 269: 12173–12178.PubMedGoogle Scholar
  9. Breyer, M.D., Jacobson, H.R., Davis, L.S. and Breyer, R.M., 1993, In situ hybidization and localization of mRNA for the rabbit prostaglandin EP3 receptor. Kidney Int., 43: 1372–1378.CrossRefGoogle Scholar
  10. Bunce, K.T. Clayton, N.M., Coleman, R.A., Collington, E.W., Finch, H., Humphrey, P.P.A., Reeves, J.J., Sheldrick, R.L.G. and Stables, R., 1990, GR63799X-a novel prostanoid with selectivity for EP3 receptors. Adv. Prostaglandin Thromboxane Leukotriene Res., 21: 379–382.Google Scholar
  11. Bygdeman, M. Prostaglandins for termination of pregnancy.In: Therapeutic Applications of Prostaglandins. ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), pp85-91.Google Scholar
  12. Caldwell, A.G., Harris, C.J., Stepney, R. and Whittaker, N., 1979, Hydantoin prostaglandin analogues, potent and selective inhibitors of platelet aggregation. J. Chem. Soc. Chem. Comm., 101: 561–562.CrossRefGoogle Scholar
  13. Coleman, R.A., Grix, S.P., Head, S.A., Louttit, J.B., Mallett, A. and Sheldrick, R.L.G., 1994a, A novel inhibitory receptor in piglet saphenous vein. Prostaglandins, 47: 151–168.PubMedGoogle Scholar
  14. Coleman, R.A., Kennedy, I., Humphrey, P.P.A., Bunce, K. & Lumley, P. Prostanoids and their receptors. In: Comprehensive Medicinal Chemistry Vol. 3. Membranes and Receptors ed. J.C. Emmett Pergamon Press, Oxford.(1990), pp643–714Google Scholar
  15. Coleman, R.A., Kennedy, I. and Sheldrick, R.L.G., 1987, Evidence for the existence of three subtypes of PGE2-senstive (EP-) receptors. Br. J. Pharmacol., 91: 323P.Google Scholar
  16. Coleman, R.A., Mallett, A. and Sheldrick, R.L.G., 1995, EP4-receptors and cyclic AMP pig venous smooth muscle: evidence with agonists and the EP4-antagonist, AH 22921. Adv. Prostaglandin Thromboxane Leukotriene Res. 23: 241–246.Google Scholar
  17. Coleman, R.A., Smith, W.L. and Narumiya, S., 1994b, Classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev., 46: 205–229.PubMedGoogle Scholar
  18. Cooper, B. and Ahern, D., 1979, Characterisation of the platelet prostaglandin D2 receptor. J. Clin. Invest., 64: 586–590.PubMedCrossRefGoogle Scholar
  19. Cooper, B., Schafer, A.I., Puchalsky, D. and Handin, R.I., 1979, Desensitisation of prostaglandin-activated platelet adenylate cyclase. Prostaglandins, 17: 561–571.PubMedGoogle Scholar
  20. Funk, C.D., Furci, L., FitzGerald, G.A., Grygorczyk, R., Rochette, C., Bayne, M.A., Abramovitz, M., Adam, M., and Metters, K.M., 1993, Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem., 268: 26767–26772.PubMedGoogle Scholar
  21. Gardiner, P.J., 1986, Characterisation of prostanoid relaxant /inhibitory receptors (ψ) using a highly selective agonist, TR4979. Br. J. Pharmacol., 87: 45–56.PubMedCrossRefGoogle Scholar
  22. Gardiner, P.J. and Collier, H.O.J., 1980, Specific receptors for prostaglandins in airways. Prostaglandins, 19: 819–841.PubMedGoogle Scholar
  23. Halushka, P.V., Mais, D.E., Mayeux, P.R. and Morinelli, T.A., 1989, Thromboxane, prostaglandin and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol., 29: 213–239.CrossRefGoogle Scholar
  24. Harris, D.N., Hedberg, A., Phillips, M.B., Michel, I.M., Goldenberg, H.J. and Liu, E.C.-K., 1987, 7-Oxabicycloheptane analogs: modulators of the arachidonate cascade. Adv. Prostaglandin Thromboxane Leukotriene Res., 17: 482–486.Google Scholar
  25. Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S. and Narumiya, S., 1991, Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349: 617–620.PubMedCrossRefGoogle Scholar
  26. Hirata, M. Kakizuka, A., Aizawa, M., Ushikubi, F. and Narumiya, S., 1994, Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Nat. Acad. Sci., 91: 11192–11196.PubMedCrossRefGoogle Scholar
  27. Honda, A., Sugimoto, Y., Namba, T., Watabe, A., Irie, A., Negishi, M., Narumiya, S. and Ichikawa, A., 1993, Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. J. Biol. Chem., 268: 7759–7762.PubMedGoogle Scholar
  28. Ito, S., Okuda, E., Sugama, K., Negishi, M. and Hayaishi, O., 1990, Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea. Br. J. Pharmacol., 99: 13–14.PubMedCrossRefGoogle Scholar
  29. Jackson, P.S. and Jessup, R., 1984, Secondary pharmacological properties of prostaglandins. Vet. Rec., 114: 168.PubMedCrossRefGoogle Scholar
  30. Kennedy, I., Coleman, R.A., Humphrey, P.P.A., Levy, G.P. and Lumley, P., 1982, Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins 24: 667–689.PubMedGoogle Scholar
  31. Kitanaka, J., Hasimoto, H., Sugimoto, Y., Negishi, M., Aino, H., Gotoh, M., Ichikawa, A. and Baba, A., 1994, Cloning and expression of a cDNA for rat prostaglandin PGF2α receptor. Prostaglandins, 48: 31–41.PubMedGoogle Scholar
  32. Lake, S., Gullberg, H., Wahlqvist, J., Sjogren, A.-M., Kinhult, A., Lind, P., Hellström-Lindahl, E. and Stjernschantz, J., 1994, Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor. FEBS Let., 355: 317–325.CrossRefGoogle Scholar
  33. Linet, O. Prostaglandins in erectile dysfunction. In: Therapeutic Applications of Prostaglandins, ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), PP105–121.Google Scholar
  34. Mais, D.E., Saussy, D.L., Chaikhouni, J.R., Kochel, P.J., Knapp, D.R., Hamanaka, N. and Halushka, P.V., 1985, Pharmacological characterisation of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. J. Pharmacol. Exp. Ther., 233: 418–424.PubMedGoogle Scholar
  35. Malmsten, C., 1976, Some biological effects of prostaglandin analogs. Life Sci., 18: 169–176.PubMedCrossRefGoogle Scholar
  36. Merritt, J.E., Hallam, T.J., Brown, A.M., Boyfield, I., Cooper, D.G., Hickey, D.M.B., Jaxa-Chamiec, A.A., Kaumann, A.J., Keen, M., Kelly, E., Kozlowski, U., Lynham, J.A., Moores, K.E., Murray, M.J. and Rink, T.J., 1991, Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br. J. Pharmacol., 102: 251–259.PubMedCrossRefGoogle Scholar
  37. Moncada, S., 1982, Biological importance of prostacyclin. Br. J. Pharmacol., 76: 3–31.PubMedCrossRefGoogle Scholar
  38. Morrow, J.D., Hill, K.E., Burk, R.F., Nammour, T.M., Badr, K.F. and Roberts L.J., 1990, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclo-oxygenase, free radical-catalysed mechanism. Proc. Nat. Acad. Sci., 87: 9383–9387.PubMedCrossRefGoogle Scholar
  39. Namba, T., Oida, H., Sugimoto, Y., Kakizuka, A., Negishi, M., Ichikawa, A. and Narumiya, S., 1994, cDNA cloning of a mouse prostacyclin receptor; multiple signalling pathways and expression in thymic medulla. J. Biol. Chem., 269: 9986–9992.PubMedGoogle Scholar
  40. Namba, T., Sugimoto, Y., Hirata, M., Hayashi, Y., Honda, A., Watabe, A., Negishi, M., Ichikawa, A. and Narumiya, S., 1992, Mouse thromboxane A2 receptor: cDNA cloning, expression and northern blot analysis. Biochem Biophys Res Commun, 184: 1197–1203.PubMedCrossRefGoogle Scholar
  41. Namba, T., Sugimoto, Y, Negishi, M., Irie, A., Ushikubi, F., Kakizuka, A., Ito, S., Ichikawa, A., and Narumiya, S., 1993, Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature, 365: 166–170.PubMedCrossRefGoogle Scholar
  42. Niais, A.T., Vardey, C.J., Denyer, L.H., Thomas, M., Sparrow, S J., Shepherd, G.D. and Coleman, R.A., 1993, AH13205, a selective prostanoid EP2-receptor agonist. Cardiovasc. Drug Rev., 11: 165–179.CrossRefGoogle Scholar
  43. Nüsing, R.M., Hirata, M., Kakizuka, A., Eki, T., Ozawa, K. and Narumiya, S., 1993, Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J. Biol. Chem., 268: 25253–25259.PubMedGoogle Scholar
  44. Ogletree, M.L. and Allen, G.T., 1992, Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea-pig smooth muscles. J. Pharmacol. Exp. Then, 260: 789–794.Google Scholar
  45. Pickles, V.R. The myometrial actions of six prostaglandins: consideration of a receptor hypothesis. Nobel Symposium, Vol 2: Prostaglandins. Bergström, S., Samuelsson, B. Almquist & Wicksell, Stockholm (1967) pp79–83.Google Scholar
  46. Raychowdhury, M.K., Yukawa, M., Collins, L.J., McGrail, S.H., Kent, K.C. and Ware, J.A., 1994, Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane receptor. J. Biol. Chem., 269: 19256–19261.PubMedGoogle Scholar
  47. Reeves, J.J., Bunce, K.T., Sheldrick, R.L.G. and Stables, R., 1988, Evidence for the PGE receptor subtype mediating inhibition of acid secretion in the rat. Br. J. Pharmacol., 95: 805P.CrossRefGoogle Scholar
  48. Regan, J.W., Bailey, T.J., Donello, J.E., Pierce, K.L., Pepperl, D.J., Zhang, D., Kedzie, K.M., Fairbairn, C.E., Bogardus, A.M., Woodward, D.F. and Gil, D.W., 1994, Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxy termini. Br. J. Pharmacol., 112: 377–385.PubMedCrossRefGoogle Scholar
  49. Regan, J.W., Bailey, T.J., Pepperl, D.J., Pierce, K.L., Bogardus, A.M., Donello, J.E., Fairbairn, C.E., Kedzie, K.M., Woodward, D.F. and Gil, D.W., 1994, Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol. Pharmacol., 46: 213–220.PubMedGoogle Scholar
  50. Robertson, P.R., 1986, Characterization and regulation of prostaglandin and leukotriene receptors: an overview. Prostaglandins, 31: 395–411.PubMedGoogle Scholar
  51. Senior, J., Sangha, R., Baxter, G.S., Marshall, K. and Clayton, J.K., 1992, In vitro characterization of prostanoid FP-, DP-, IP-and TP-receptors in the non-pregnant human myometrium. Br. J. Pharmacol., 107: 215–221.PubMedCrossRefGoogle Scholar
  52. Sewing, K.-F.R. and Beinborn, M., 1990, Eicosanoid receptors of the gastrointestinal tract. Adv. Prostaglandin Thromboxane Leukotriene Res., 20: 138–145.Google Scholar
  53. Simon, B., Kather, H. and Kommereil, B., 1980, Activation of human colonic mucosal adenylate cyclase by prostaglandins. Adv. Prostaglandin Thromboxane Res. 8: 1617–1620.PubMedGoogle Scholar
  54. Sinzinger, H. Prostaglandins in ischaemic peripheral vascular disease. In: Therapeutic Applications of Prostaglandins, ed. J. Vane & J. O’Grady, Edward Arnold, Boston (1993), PP209–218.Google Scholar
  55. Smith, G.C.S., Coleman, R.A. and McGrath, J.C., 1994, Characterisation of dilator prostanoid receptors in fetal rabbit ductus arteriosus. J. Pharmacol. Exp. Ther., 271: 390–396.PubMedGoogle Scholar
  56. Stjernschantz, J., 1995, Prostaglandins as ocular hypotensive agents; development of an analogue for glaucoma treatment. Adv. Prostaglandin Thromboxane Leukotriene Res., 23: 63–68.Google Scholar
  57. Strong, P., Coleman, R.A. and Humphrey, P.P.A., 1992, Prostanoid-induced inhibition of lipolysis in rat isolated adipocytes: probable involvement of EP3 receptors. Prostaglandins, 43: 559–566.PubMedGoogle Scholar
  58. Sugimoto, Y., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., Kakizuka, A., Narumiya, S. and Ichikawa, A., 1994, Cloning and expression of a cDNA for mouse prostglandin F receptor. J. Biol. Chem. 269: 1356–1360.PubMedGoogle Scholar
  59. Sugimoto, Y., Namba, T., Honda, A., Hayashi, Y., Negishi, M., Ichikawa, A. and Narumiya, S., 1992, Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J. Biol. Chem., 267: 6463–6466.PubMedGoogle Scholar
  60. Takeuchi, K., Abe, T., Takahashi, N. and Abe, K., 1993, Molecular cloning and intrarenal localization of rat prostaglandin E2 receptor EP3 subtype. Biochem. Biophys. Res. Commun., 194: 885–891.PubMedCrossRefGoogle Scholar
  61. Thierauch, K.-H., Stürzebecher, C. St., Schillinger, E., Rehwinkel, H., Radüchel, B., Skuballa, W. and Vörbruggen, H., 1988, Stable 9β-or 11α-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2 receptor. Prostaglandins, 35: 853–868.Google Scholar
  62. Town, M.H. Casals-Stenzel, J. and Schillinger, E., 1983, Pharmacological and cardiovascular properties of a hydantoin derivative, BW245C, with high affinity and selectivity for PGD2 receptors. Prostaglandins, 25: 13–28.PubMedGoogle Scholar
  63. Watabe, A., Sugimoto, Y., Honda, A., Irie, A., Namba, T., Negishi, M., Ito, S., Narumiya, S. and Ichikawa, A., 1993, Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. J. Biol. Chem., 268: 20175–20178.PubMedGoogle Scholar
  64. Witherspoon, D.M., Lamond, D.R., Thompson, F.N. and Stevenson, W., 1975, Efficacy of a prostaglandin analogue in reproduction in the cycling mare. Theriogenology, 3: 21–30.PubMedCrossRefGoogle Scholar
  65. Woodward, D.F., Fairbairn, C.E., Krauss, A.H.-P., Lawrence, R.A. and Protzman, C.E., 1995, Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins. J. Pharmacol. Exp. Ther., 273: 285–291.PubMedGoogle Scholar
  66. Woodward, D.F. and Lawrence, R.A., 1994, Prostanoid induced Ca2+ signals in Swiss 3T3 cells are mediated by a single (FP) receptor. Biochem. Pharmacol., (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Robert A. Coleman
    • 1
  1. 1.Department of Pharmacology 1Glaxo Wellcome Research & Development LtdWare, HertfordshireUK

Personalised recommendations